Langford BJ, So M, Simeonova M, Leung V, Lo J, Kan T, et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. Lancet Microbe. 2023;4:e179–e191.

Article  PubMed  PubMed Central  Google Scholar 

WHO. Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024.

Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin Infect Dis. 2020;71:e523–e529.

Article  CAS  PubMed  Google Scholar 

Dance A. Five ways science is tackling the antibiotic resistance crisis. Nature. 2024;632:494–6.

Article  CAS  PubMed  Google Scholar 

Huang Y, Zhu Y, Yue H-Y, Liu Y-Y, Deng L-M, Lv L, et al. Flavomycin restores colistin susceptibility in multidrug-resistant Gram-negative bacteria. mSystems. 2024;9:e0010924.

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Zhou H, Kong J, Chen H, Chen L, Tang M, et al. Verapamil increases susceptibility of colistin-resistant Acinetobacter baumannii to colistin. Int J Antimicrob Agents. 2024;64:107233.

Article  CAS  PubMed  Google Scholar 

Hussein M, Kang Z, Neville SL, Allobawi R, Thrombare V, Koh AJJ, et al. Metabolic profiling unveils enhanced antibacterial synergy of polymyxin B and teixobactin against multidrug-resistant Acinetobacter baumannii. Sci Rep. 2024;14:27145.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed SA, Jordan RL, Isseroff RR, Lenhard JR. Potential synergy of fluoxetine and antibacterial agents against skin and soft tissue pathogens and drug-resistant organisms. Antibiotics. 2024;13:1165.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoshdel N, Noursalehigarakani M, Seghatoleslami ZS, Hadavand F, Eghbal E, Nasiri MJ, et al. Efficacy of Ceftazidime-avibactam in treating gram-negative infections: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2025;44:767–78.

Article  PubMed  PubMed Central  Google Scholar 

Zhu L, Li Z, Yuan Z, Li H, Zhou T, Chen Y, et al. Repurposing antitumor drugs for the treatment of non-oncological diseases: mechanistic insights, clinical evidence, and future perspectives. Biochem Pharmacol. 2025;240:117118.

Article  CAS  PubMed  Google Scholar 

Kumar S, Tarnow-Mordi W, Mol BW, Flenady V, Liley HG, Badawi N, et al. iSEARCH investigators. intrapartum sildenafil to improve perinatal outcomes: a randomized clinical trial. JAMA. 2025;334:149–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, et al. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017;9:eaai9048.

Article  PubMed  Google Scholar 

Liu J, Yang P, Tian H, Zhen K, McCabe C, Zhao L, et al. Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. J Transl Int Med. 2022;10:125–33.

Article  PubMed  PubMed Central  Google Scholar 

Sonowal H, Rice WG, Bejar R, Byun JY, Jung SH, Sinha R, et al. Preclinical development of tuspetinib for the treatment of acute myeloid leukemia. Cancer Res Commun. 2025;5:74–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daver N, Lee K, Jung C, Yoon S, Arellano M, Yoon J, et al. First-in-human (FIH) FLT3 and SYK inhibitor HM43239 shows single-agent activity in patients (pts) with relapsed or refractory (R/R) FLT3-mutated and wild-type acute myeloid leukemia (AML). Blood. 2021;138:702.

Article  Google Scholar 

Daver N, Lee K, Jung C, Soo Y, Arellano M, Jonas B, et al. HM43239, a novel small molecule inhibitor of FLT3, in acute myeloid leukemia (AML) with and without FMS-like tyrosine kinase 3 (FLT3) mutations: phase 1/2 study. Blood. 2020;136:1.

Article  Google Scholar 

Popowska M, Osińska M, Rzeczkowska M. N-acetylglucosamine-6-phosphate deacetylase (NagA) of Listeria monocytogenes EGD, an essential enzyme for the metabolism and recycling of amino sugars. Arch Microbiol. 2012;194:255–68.

Article  CAS  PubMed  Google Scholar 

Park JT, Uehara T. How bacteria consume their own exoskeletons (turnover and recycling of cell wall peptidoglycan). Microbiol Mol Biol Rev. 2008;72:211–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keffeler EC, Parthasarathy S, Abdullahi ZH, Hancock LE. Metabolism of Poly-β1,4-N-acetylglucosamine substrates and importation of N-acetylglucosamine and glucosamine by Enterococcus faecalis. J Bacteriol. 2021;203:e0037121.

Article  PubMed  PubMed Central  Google Scholar 

Ahangar MS, Furze CM, Guy CS, Cooper C, Maskew KS, Graham B, et al. Structural and functional determination of homologs of the Mycobacterium tuberculosis N-acetylglucosamine-6-phosphate deacetylase (NagA). J Biol Chem. 2018;293:9770–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okeke IN, de Kraker MEA, Van Boeckel TP, Kumar CK, Schmitt H, Gales AC, et al. The scope of the antimicrobial resistance challenge. Lancet. 2024;403:2426–38.

Article  CAS  PubMed  Google Scholar 

Yang Q, Pogue JM, Li Z, Nation RL, Kaye KS, Li J. Agents of last resort: an update on polymyxin resistance. Infect Dis Clin North Am. 2020;34:723–50.

Article  PubMed  Google Scholar 

Azad MAK, Nation RL, Velkov T, Li J. Mechanisms of polymyxin-induced nephrotoxicity. Adv Exp Med Biol. 2019;1145:305–19.

Article  CAS  PubMed  Google Scholar 

Tuon FF, Rocha JL, Gasparetto J. Polymyxin B and colistin: the economic burden of nephrotoxicity against multidrug-resistant bacteria. J Med Econ. 2019;22:158–62.

Article  PubMed  Google Scholar 

Lu J, Azad MAK, Moreau JLM, Zhu Y, Jiang X, Tonta M, et al. Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity. Cell Mol Life Sci. 2022;79:296.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Azad MAK, Thompson PE, Roberts KD, Velkov T, Zhu Y, et al. Transcriptomic responses to polymyxin B and analogues in human kidney tubular cells. Antibiotics. 2023;12:415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lisnyak Y, Martynov A, Farber B. Interactions between antimicrobial peptides and targets responsible for their nephrotoxic action: molecular dynamics simulations. Curr Drug Saf. 2024;19:342–9.

Article  CAS  PubMed  Google Scholar 

Gil-Gil T, Laborda P, Martínez JL, Hernando-Amado S. Use of adjuvants to improve antibiotic efficacy and reduce the burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2024;17:1.

Google Scholar 

De Oliveira DMP, Bohlmann L, Conroy T, Jen FE, Everest-Dass A, Hansford KA, et al. Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis. Sci Transl Med. 2020;12:eabb3791.

Article  PubMed  Google Scholar 

Tsai CN, MacNair CR, Cao MPT, Perry JN, Magolan J, Brown ED, et al. Targeting two-component systems uncovers a small-molecule inhibitor of Salmonella virulence. Cell Chem Biol. 2020;27:793–805.

Article  CAS  PubMed  Google Scholar 

Song M, Liu Y, Huang X, Ding S, Wang Y, Shen J, et al. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens. Nat Microbiol. 2020;5:1040–50.

Article  CAS  PubMed  Google Scholar 

Farha MA, El-Halfawy OM, Gale RT, MacNair CR, Carfrae LA, Zhang X, et al. Uncovering the hidden antibiotic potential of cannabis. ACS Infect Dis. 2020;6:338–46.